Khan ZA, et al. Methotrexate: A detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 2012; 9:151–169. doi: 10.1517/17425247.2012.642362
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11:694–703. doi: 10.1634/theoncologist.11-6-694
Mallipattu SK, Ross MJ. Methotrexate in the urine. Kidney Int 2011; 80:226. doi: 10.1038/ki.2011.97
Howard SC, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016; 21:1471–1482. doi: 10.1634/theoncologist.2015-0164
Lee JS, et al. Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 2020; 40:765–770. doi: 10.1007/s00296-020-04547-y
Sparks JA, et al. Effect of low-dose methotrexate on eGFR and kidney adverse events: A randomized clinical trial. J Am Soc Nephrol 2021; 32:3197–3207. doi: 10.1681/ASN.2021050598
Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006
Budancamanak M, et al. Protective effects of thymoquinone and methotrexate on the renal injury in collagen-induced arthritis. Arch Toxicol 2006; 80:768–776. doi: 10.1007/s00204-006-0094-0